Omalizumab (Xolair®) is a recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response. Xolair is used to treat severe, persistent asthma. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. BioVision’s BioSimTM anti-Omalizumab ELISA kit is designed to detect antibody against Omalizumab with high specificity and sensitivity in biological matrices.
产品特点
Easy, convenient, sensitive and time-saving method toqualitative determination of antibody against Omalizumab (Xolair) in human serum and plasma.
Cross Reactivity: Omalizumab (Xolair
